- Open
- 0.57
- High
- 0.60
- Low
- 0.57
- Close
- 0.57
- Change
- -0.02 (-4.35%)
- Volume
- 228,872
| 16 Nov 2026 | 07:00:07 | Promising Interim Phase I Data for miRisten in AML |
| 11 Nov 2026 | 07:00:05 | Lipisiran™ cardiovascular in vitro study completed |
| 9 Nov 2026 | 07:00:07 | Clinical Trial Agreement signed for miRisten |
| 30 Sept 2026 | 07:00:04 | Interim Results |
| 9 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 30 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.
| 16 Nov 2026 | 07:00:07 | Promising Interim Phase I Data for miRisten in AML |
| 11 Nov 2026 | 07:00:05 | Lipisiran™ cardiovascular in vitro study completed |
| 9 Nov 2026 | 07:00:07 | Clinical Trial Agreement signed for miRisten |
| 30 Sept 2026 | 07:00:04 | Interim Results |
| 9 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 30 Apr 2024 | Annual Report and Accounts (to 2023-12-31) |
Thalia Therapeutics PLC is a holding company for N4 UK and Nanogenics, providing funding for their operations. N4 UK develops nanoparticle silica delivery systems to enhance the delivery and effectiveness of cancer treatments and vaccines. Nanogenics focuses on a Liptide® platform for delivering proprietary siRNA sequences to silence fibrotic genes. The company is advancing a pipeline of RNA-based therapeutics, particularly targeting cardiovascular diseases, while also exploring gene therapy candidates for glaucoma.
| 29 Sept 2026 | 07:24:01 | New Patent Granted for miRisten in China |
| 25 Sept 2026 |
| AIM movers: Bango performance improves and Safestay revenues fall |
| 17 Jul 2026 | Thalia Therapeutics eyes clinical-stage transition as shareholders vote on Sanmirna deal |
| 10 Jul 2026 | Week Ahead: Rio Tinto, Barratt Redrow, Antofagasta, Ocado |
| 29 Jun 2026 | Thalia Therapeutics goes clinical-stage overnight with Sanmirna acquisition |
| 24 Jun 2026 | AIM Market Roundup: Thalia Therapeutics, Novacyt, TMT Investments |
| 24 Jun 2026 | AIM movers: Thalia Therapeutics acquisition and Velocity Composites second half hit by business mix |
| 29 Sept 2026 | 07:24:01 | New Patent Granted for miRisten in China |
| 25 Sept 2026 |
| AIM movers: Bango performance improves and Safestay revenues fall |
| 17 Jul 2026 | Thalia Therapeutics eyes clinical-stage transition as shareholders vote on Sanmirna deal |
| 10 Jul 2026 | Week Ahead: Rio Tinto, Barratt Redrow, Antofagasta, Ocado |
| 29 Jun 2026 | Thalia Therapeutics goes clinical-stage overnight with Sanmirna acquisition |
| 24 Jun 2026 | AIM Market Roundup: Thalia Therapeutics, Novacyt, TMT Investments |
| 24 Jun 2026 | AIM movers: Thalia Therapeutics acquisition and Velocity Composites second half hit by business mix |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £34m | -0.2% | |
| £14m | +0.2% | |
THATThalia Therapeutics PLC | £10m | -0.1% |
| £10m | -0.2% | |
| £5m | -0.4% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £34m | -0.2% | |
| £14m | +0.2% | |
THATThalia Therapeutics PLC | £10m | -0.1% |
| £10m | -0.2% | |
| £5m | -0.4% |